Seven Eight Capital’s Maravai LifeSciences MRVI Stock Holding History

Seven Eight Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14,712	Closed	-$105K	–	870
2024 Q2	$105K	Sell	14,712 -45,341	-76%	-$391K	0.01%	664
2024 Q1	$521K	Buy	+60,053	New	+$406K	0.05%	446
2023 Q4	–	Sell	-17,187	Closed	-$172K	–	765
2023 Q3	$172K	Buy	+17,187	New	+$189K	0.02%	565
2023 Q1	–	Sell	-177,480	Closed	-$2.54M	–	547
2022 Q4	$2.54M	Buy	+177,480	New	+$2.79M	0.66%	27
2022 Q2	–	Sell	-31,928	Closed	-$1.13M	–	538
2022 Q1	$1.13M	Buy	+31,928	New	+$1.07M	0.15%	197
2021 Q3	–	Sell	-5,752	Closed	-$240K	–	672
2021 Q2	$240K	Buy	+5,752	New	+$223K	0.03%	533

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Seven Eight Capital's MRVI Position: Q3 2024 in Review

Seven Eight Capital sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 14,712 shares — an estimated $105K sold.

Seven Eight Capital first reported a position in MRVI in Q2 2021 and held it in 6 quarters. The position peaked at $2.54M in Q4 2022. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

Seven Eight Capital reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
Seven Eight Capital sold 14,712 Maravai LifeSciences shares in Q3 2024, an estimated $105K.
Seven Eight Capital first reported a position in Maravai LifeSciences in Q2 2021 and held it in 6 quarters.
Seven Eight Capital's Maravai LifeSciences position peaked at $2.54M in Q4 2022.
217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.